Prognostic significance of AGR2 in pancreatic ductal adenocarcinoma

Histology and Histopathology

Volumn 24, Issue 9, 2009, Pages 1121-1128

  Riener, Marc Oliver ^a   Pilarsky, Christian ^b   Gerhardt, Josefine ^a   Grützmann, Robert ^b   Fritzsche, Florian R ^a   Bahra, Marcus ^c   Weichert, Wilko ^c   Kristiansen, Glen ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

AGR2; Immunohistochemistry; mRNA; Pancreatic adenocarcinoma; Prognosis

Indexed keywords

AGR2 PROTEIN, HUMAN; MESSENGER RNA; MONOCLONAL ANTIBODY; PROTEIN;

ADENOCARCINOMA; AGED; ARTICLE; CELL LINE; FEMALE; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; METABOLISM; MICRODISSECTION; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; SEX DIFFERENCE; SURVIVAL; TIME; TISSUE MICROARRAY; TUMOR CELL LINE;

ADENOCARCINOMA; AGED; ANTIBODIES, MONOCLONAL; CARCINOMA, PANCREATIC DUCTAL; CELL LINE; CELL LINE, TUMOR; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MICRODISSECTION; PANCREATIC NEOPLASMS; PROGNOSIS; PROTEINS; RNA, MESSENGER; SEX FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TISSUE ARRAY ANALYSIS;

EID: 70349758603     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Aberger F., Weidinger G., Grunz H. and Richter K. (1998). Anterior specification of embryonic ectoderm: the role of the Xenopus cement gland-specific gene XAG-2, Mech. Dev. 72, 115-130.
2. Butturini G., Stocken D.D., Wente M.N., Jeekel H., Klinkenbijl J.H., Bakkevold K.E., Takada T., Amano H., Dervenis C., Bassi C., Buchler M.W. and Neoptolemos J.P. (2008). Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials, Arch Surg 143, 75-83; discussion 83.
3. Fletcher G.C., Patel S., Tyson K., Adam P.J., Schenker M., Loader J.A., Daviet L., Legrain P., Parekh R., Harris A.L. and Terrett J.A. (2003). hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene C4.4a and dystroglycan. Br. J. Cancer 88, 579-585.
4. Fritzsche F.R., Dahl E., Pahl S., Burkhardt M., Luo J., Mayordomo E., Gansukh T., Dankof A., Knuechel R., Denkert C., Winzer K.J., Dietel M. and Kristiansen G. (2006). Prognostic relevance of AGR2 expression in breast cancer. Clin. Cancer Res. 12, 1728-1734.
5. Fritzsche F.R., Dahl E., Dankof, A., Burkhardt, M., Pahl, S., Petersen, I., Dietel, M. and Kristiansen, G. (2007). Expression of AGR2 in non small cell lung cancer, Histol. Histopathol. 22, 703-708.
6. Grutzmann R., Foerder M., Alldinger I., Staub E., Brummendorf T., Ropcke S., Li X., Kristiansen, G., Jesnowski, R., Sipos, B., Lohr, M., Luttges, J., Ockert, D., Kloppel, G., Saeger, H. D. and Pilarsky, C. (2003). Gene expression profiles of microdissected pancreatic ductal adenocarcinoma, Virchows Arch. 443, 508-517.
7. Hamilton S. and Aaltonen L. (2000). 1st ed. Lyon. IARC Press.
8. Infante J.R., Matsubayashi H., Sato N., Tonascia J., Klein A.P., Riall T.A., Yeo C., Iacobuzio-Donahue C. and Goggins M. (2007). Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma, J. Clin. Oncol. 25, 319-325.
9. Innes H.E., Liu D., Barraclough R., Davies M.P., O'Neill P.A., Platt-Higgins A., de Silva Rudland S., Sibson D.R. and Rudland P.S. (2006). Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients Br. J. Cancer 94, 1057-1065.
10. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T. and Thun M.J. (2008). Cancer Statistics. CA Cancer J Clin.
11. Komiya T., Tanigawa Y. and Hirohashi S. (1999). Cloning of the gene gob-4, which is expressed in intestinal goblet cells in mice. Biochim. Biophys. Acta 1444, 434-438.
12. Kreiger N., Lacroix J. and Sloan M. (2001). Hormonal factors and pancreatic cancer in women. Ann. Epidemiol. 11, 563-567.
13. Kristiansen G., Schluns K., Yongwei Y., Dietel M. and Petersen I. (2002). CD10 expression in non-small cell lung cancer. Anal. Cell Pathol. 24, 41-46.
14. Kristiansen G., Schluns K., Yongwei Y., Denkert C., Dietel M. and Petersen I. (2003). CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. Br. J. Cancer 88, 231-236.
15. Kristiansen G., Yu Y., Schluns K., Sers C., Dietel M. and Petersen I. (2003). Expression of the cell adhesion molecule CD146/MCAM in non-small cell lung cancer. Anal. Cell. Pathol. 25, 77-81.
16. Kristiansen G., Pilarsky C., Wissmann C., Kaiser S., Bruemmendorf T., Roepcke S., Dahl E., Hinzmann B., Specht T., Pervan J., Stephan C., Loening S., Dietel M. and Rosenthal A. (2005). Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival, J. Pathol. 205, 359-376.
17. Kristiansen G., Jacob J., Buckendahl A.C., Grutzmann R., Alldinger I., Sipos B., Kloppel G., Bahra M., Langrehr J.M., Neuhaus P., Dietel, M. and Pilarsky C. (2006). Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times. Clin. Cancer Res. 12, 6444-6451.
18. Link B.C., Reichelt U., Schreiber M., Kaifi J.T., Wachowiak R., Bogoevski D., Bubenheim M., Cataldegirmen G., Gawad K.A., Issa R., Koops S., Izbicki J.R. and Yekebas E.F. (2007). Prognostic implications of netrin-1 expression and its receptors in patients with adenocarcinoma of the pancreas. Ann. Surg. Oncol. 14, 2591-2599.
19. Liu D., Rudland P.S., Sibson D.R., Platt-Higgins A. and Barraclough R. (2005). Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas, Cancer Res. 65, 3796-3805.
20. Missiaglia E., Blaveri E., Terris B., Wang Y.H., Costello E., Neoptolemos J.P., Crnogorac-Jurcevic T. and Lemoine N.R. (2004). Analysis of gene expression in cancer cell lines identifies candidate markers for pancreatic tumorigenesis and metastasis. Int. J. Cancer 112, 100-112.
21. Murakami Y., Uemura K., Sudo T., Hayashidani Y., Hashimoto Y., Ohge H. and Sueda T. (2008). Postoperative adjuvant chemotherapy improves survival after surgical resection for pancreatic carcinoma. J. Gastrointest. Surg. 12, 534-541.
22. Ohuchida K., Mizumoto K., Miyasaka Y., Yu J., Cui L., Yamaguchi H., Toma H., Takahata S., Sato N., Nagai E., Yamaguchi K., Tsuneyoshi M. and Tanaka M. (2007). Over-expression of S100A2 in pancreatic cancer correlates with progression and poor prognosis. J. Pathol. 213, 275-282.
23. Pilarsky C., Ammerpohl O., Sipos B., Dahl E., Hartmann A., Wellmann A., Braunschweig T., Lohr M., Jesnowski R., Friess H., Wente M.N., Kristiansen G., Jahnke B., Denz A., Ruckert F., Schackert H.K., Kloppel G., Kalthoff H., Saeger H.D. and Grutzmann R. (2008). Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling, J. Cell Mol. Med. 12, 2823-2835.
24. Pohler E., Craig A.L., Cotton J., Lawrie L., Dillon J.F., Ross P., Kernohan N. and Hupp T.R. (2004). The Barrett's antigen anterior gradient-2 silences the p53 transcriptional response to DNA damage Mol. Cell Proteomics 3, 534-547.
25. Ramachandran V., Arumugam T., Wang H. and Logsdon C.D. (2008). Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival. Cancer Res. 68, 7811-7818.
26. Ridwelski K., Meyer F., Ebert M., Malfertheiner P. and Lippert H. (2001). Prognostic parameters determining survival in pancreatic carcinoma and, in particular, after palliative treatment. Dig. Dis. 19, 85-92.
27. Smirnov D.A., Zweitzig D.R., Foulk B.W., Miller M.C., Doyle G.V., Pienta K.J., Meropol N.J., Weiner L.M., Cohen S.J., Moreno J.G., Connelly M.C., Terstappen L.W. and O'Hara S.M. (2005). Global gene expression profiling of circulating tumor cells. Cancer Res. 65, 4993-4997.
28. Sossey-Alaoui K., Vieira L., David D., Boavida M.G. and Cowell J.K. (2003). Molecular characterization of a 7p15-21 homozygous deletion in a Wilms tumor. Genes Chromosomes Cancer 36, 1-6.
29. Wagner M., Redaelli C., Lietz M., Seiler C.A., Friess H. and Buchler M.W. (2004). Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br. J. Surg. 91, 586-594.
30. Wang Z., Hao Y. and Lowe A.W. (2008). The adenocarcinomaassociated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation. Cancer Res. 68, 492-497.
31. Willett C.G., Czito B.G. and Bendell J.C. (2007). Adjuvant therapy of pancreatic cancer. Cancer J. 13, 185-191.
32. Zhang J.S., Gong A., Cheville J.C., Smith D.I. and Young C.Y. (2005). AGR2, an androgen-inducible secretory protein overexpressed in prostate cancer. Genes Chromosomes Cancer 43, 249-259.
33. Zhu H., Lam D.C., Han K.C., Tin V.P., Suen W.S., Wang E., Lam W.K., Cai W.W., Chung L.P. and Wong M.P. (2007). High resolution analysis of genomic aberrations by metaphase and array comparative genomic hybridization identifies candidate tumour genes in lung cancer cell lines. Cancer Lett. 245, 303-314.